Effects of estradiol and estradiol sulfamate on the liver of ovariectomized or ovariectomized and hypophysectomized rats.
This study was performed to evaluate and compare the effects of estradiol sulfamate (J995) and estradiol (E2) on the hepatic levels of the estrogen receptor (ER) and its mRNA, in ovariectomized (OVX) and OVX+hypophysectomized (OVXHX) female rats and to study the effects on the liver-derived serum compounds angiotensin I, triglycerides, high-density lipoprotein (HDL) and cholesterol. ER concentrations were determined using ligand-binding assay (LBA) and enzyme immuno assay (EIA), and the mRNA levels using solution hybridization. The rats were treated orally (p.o.) or subcutaneously (s.c.) for 7 days, with treatments initiated 14 days after surgery. No differences were found in ER mRNA levels between J995 and E2 treated rats. The s.c. administered estrogens increased ER levels in OVX rats. Addition of GH+DEX to OVXHX rats restored the ER to levels above those seen in intact rats, whereas simultaneous oral treatment with E2 significantly decreased ER levels again. The s.c. treatment with either J995 or E2 limited the increase caused by addition of GH+DEX. After oral treatment angiotensin I levels were increased by E2, but not by J995, while triglycerides, HDL and cholesterol levels were decreased by oral E2, J995 showing a similar pattern but was less effective. In summary, these results on hepatic ER levels and estrogen dependent compounds produced by the liver showed that J995 has a lower impact on the normal liver functions after oral treatment than E2. Thus, J995 is a very promising substance for development of oral estrogen treatment with reduced hepatic side effects.
Sahlin
Lena
L
Division for Reproductive Endocrinology, Department of Woman and Child Health, Karolinska Hospital L5:01, S-171 76 Stockholm, Sweden. lena.sahlin@kbh.ki.se
Elger
Walter
W
Hedden
Annemarie
A
Lindberg
Monica
M
Reddersen
Gudrun
G
Schneider
Birgitt
B
Schwarz
Sigfrid
S
Freyschuss
Bo
B
Eriksson
Håkan
H
D000803:Angiotensin I / Q000096:biosynthesis; D000818:Animals; D002784:Cholesterol / Q000096:biosynthesis / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology*; D004967:Estrogens / Q000378:metabolism; D005260:Female; D007124:Immunoenzyme Techniques; D007279:Injections, Subcutaneous; D008024:Ligands; D008075:Lipoproteins, HDL / Q000096:biosynthesis; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D009693:Nucleic Acid Hybridization; D010053:Ovary / Q000502:physiology*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D013449:Sulfonamides / Q000494:pharmacology*; D013997:Time Factors; D014280:Triglycerides / Q000096:biosynthesis
C119805:17-benzylestradiol 3-O-sulfamate; D004791:Enzyme Inhibitors; D004967:Estrogens; D008024:Ligands; D008075:Lipoproteins, HDL; D012333:RNA, Messenger; D013449:Sulfonamides; D014280:Triglycerides; D004958:Estradiol; D000803:Angiotensin I; D002784:Cholesterol